ArticleFrontiers in oncology2025
MS-stable/TMB-high pleomorphic liposarcoma successfully treated with pembrolizumab: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pleomorphic liposarcoma (PLPS) is a rare and aggressive subtype of liposarcoma with limited treatment options. Despite studies on immune checkpoint inhibitors (ICIs) in sarcomas, there have been few reports involving PLPS. Furthermore, the significance of tumor mutation burden (TMB)-high, a known biomarker for ICIs in various solid tumors, remains unclear in sarcomas. Herein, we report the case of a 41-year-old man with postoperative liver metastasis of microsatellite (MS)-stable/TMB-high PLPS who achieved successful remission with pembrolizumab, an anti-programmed cell death protein 1 inhibitor. Initially, the patient underwent extensive resection for primary PLPS in the distal left thigh. The diagnosis of lung metastases 3 months after prompted five courses of doxorubicin and ifosfamide, resulting in stable disease. Subsequent thoracoscopic pulmonary metastasectomy allowed surgical removal of the lung metastases. However, multiple liver metastases developed 9 months following the primary extensive resection. Cancer genome profiling revealed a mutation in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.